Angiotensin Receptor Neprilysin Inhibitor Therapy Improves Ejection Fraction in Patients with Systolic Heart Failure

The PARADIGM-HF study showed that angiotensin receptor-neprilysin inhibitor (ARNI) therapy with sacubitril/valsartan significantly reduced cardiovascular mortality, heart failure hospitalization, and all-cause mortality compared to ace inhibitor therapy with enalapril in patients with heart failure with reduced ejection fraction (HFrEF). Since being fast tracked for HFrEF treatment in 2015, ARNI has been studied in various aspects related to efficacy and long-term effects. However, the effect of ARNI specifically on ejection fraction (EF) in patients with HFrEF on guideline directed medical therapy (GDMT) remains unknown.
Source: Journal of Cardiac Failure - Category: Cardiology Authors: Tags: 135 Source Type: research